Article
Medicine, Research & Experimental
Shuhua Wei, Fenghua Wei, Mengyuan Li, Yuhan Yang, Jingwen Zhang, Chunxiao Li, Junjie Wang
Summary: Sorafenib, a multi-kinase inhibitor, has been approved for cancer treatment, especially hepatocellular carcinoma (HCC). However, many cancer patients acquire drug resistance to sorafenib in subsequent treatment, and the immunological mechanisms behind this resistance are still unclear. This review focuses on the immunoregulatory effects of sorafenib on the tumor microenvironment, the potential immunological mechanisms of therapeutic resistance, and the combination of sorafenib with immunotherapy to improve efficacy.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Oncology
Haoming Xia, Ziyue Huang, Zhensheng Wang, Shuqiang Liu, Xudong Zhao, Junqi You, Yi Xu, Judy Wai Ping Yam, Yunfu Cui
Summary: Glucometabolic reprogramming plays a significant role in the development and treatment of hepatocellular carcinoma (HCC). By altering the glucose metabolism pathway, HCC cells can survive and thrive in nutrient-poor tumor microenvironments and evade immune surveillance. Targeted interventions against glucose metabolism and signaling pathways hold promising prospects for HCC therapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Endocrinology & Metabolism
David Standing, Prasad Dandawate, Shrikant Anant
Summary: Prolactin (PRL) is a peptide hormone secreted by the anterior pituitary gland, and its receptor PRLR plays a role in various cancers. PRL binding to PRLR leads to downstream signaling that promotes cancer progression. The PRLR signaling pathway is an attractive target for drug development in cancer treatment.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Yahui Wu, Rongtao Zhu, Mengyang Zhou, Jingjing Liu, Kai Dong, Senfeng Zhao, Jiahui Cao, Weijie Wang, Chenguang Sun, Shitao Wu, Fan Wang, Yupeng Shi, Yuling Sun
Summary: A bionic nanodrug delivery platform was successfully constructed in this study, consisting of a core of Lenvatinib wrapped with a pH-sensitive polymer and a shell formed by a cancer cell membrane. The prepared nanodrugs have high drug loading capacity, long-term stability, good biocompatibility, and a long retention time. In vivo experiments showed superior tumor accumulation and therapeutic effects of the nanodrug, providing a new approach to reduce side effects and improve the specific therapeutic effect of first-line clinical medications in tumor treatment.
Review
Immunology
Sihang Yu, Lei Zhou, Jiaying Fu, Long Xu, Buhan Liu, Yuanxin Zhao, Jian Wang, Xiaoyu Yan, Jing Su
Summary: There is increasing evidence showing the crucial role of the immune microenvironment, particularly the polarization state and function of macrophages, in the development of hepatocellular carcinoma. Tumor-derived exosomes in hepatocellular carcinoma act as information carriers and regulate the physiological state of cells in the microenvironment, thus controlling cancer progression. This review focuses on the role of exosome content in disease outcomes at different stages of hepatitis B virus/hepatitis C virus-induced hepatocellular carcinoma, and explores the mechanism by which macrophages contribute to hepatocellular carcinoma formation and the regulation of macrophage functions by the heterogeneity of exosome loading. The application prospects of exosome-based targeted drug delivery in immunotherapy research on hepatocellular carcinoma are also summarized.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Shuang Li, Limin Chen
Summary: Exosomes are extracellular vesicles that play important roles in cell-to-cell communication and can be stably present in various body fluids. They have a unique double-layer saclike structure and reflect the characteristics of their host cells. Exosomes derived from hepatocellular carcinoma cells show heterogeneity in their cargo. Additionally, exosomes are capable of efficiently delivering cargoes to target cells, which significantly impact HCC progression, including tumor occurrence, development, metastasis, immune regulation, and drug resistance. Previous studies have demonstrated wide applications of exosomes in the diagnosis and treatment of HCC. This review discusses recent findings on the significant roles of exosomes in HCC, focusing on their effects and underlying mechanisms in regulating HCC progression and their potential clinical value as biomarkers and therapeutic targets.
FRONTIERS IN ONCOLOGY
(2022)
Review
Cell Biology
Sisi Yang, Chengwei Cai, Huanqiu Wang, Xueqing Ma, Anwen Shao, Jifang Sheng, Chengbo Yu
Summary: Hepatocellular carcinoma (HCC) is a common malignant tumor worldwide, and traditional antitumor drugs have limitations. The application of nanotechnology plays a significant role in improving drug delivery and selective accumulation.
CELL COMMUNICATION AND SIGNALING
(2022)
Article
Pharmacology & Pharmacy
Mariangela Garofalo, Federica Bellato, Salvatore Magliocca, Alessio Malfanti, Lukasz Kuryk, Beate Rinner, Samuele Negro, Stefano Salmaso, Paolo Caliceti, Francesca Mastrotto
Summary: This study explored the use of polymer-coated oncolytic viruses for the treatment of hepatocellular carcinoma, showing higher therapeutic efficacy in cells expressing high levels of ASGPR. The polymer coating altered the viral properties, enhancing infectivity and immunogenic cell death compared to naked viruses.
Review
Biochemistry & Molecular Biology
Kuo-Shyang Jeng, I-Shyan Sheen, Shu-Sheng Lin, Chuen-Miin Leu, Chiung-Fang Chang
Summary: Endoglin (CD105) is a vital protein associated with angiogenesis in hepatocellular carcinoma (HCC), potentially serving as a diagnostic or prognostic factor. Combining TRC105, an antibody against endoglin, with sorafenib can achieve partial response. While antiangiogenic therapy carries risks, combination therapy with endoglin inhibitors or other targeted therapies shows promise.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Qian Chen, Xiao-Wei Zhou, Ai-Jun Zhang, Kang He
Summary: ACTN1 is significantly upregulated in HCC tissues and acts as a tumor promoter by suppressing Hippo signaling through physical interaction with MOB1. Therefore, ACTN1 may serve as a potential prognostic marker and therapeutic target for HCC.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Linlin Li, Yifang Zou, Lingzhi Wang, Leilei Yang, Yutong Li, Anqi Liao, Zheng Chen, Zhuo Yu, Jianfeng Guo, Shulan Han
Summary: This study confirmed the potential of scutellarin for inducing immunogenic cell death in hepatocellular carcinoma cells. To enable its in vivo application, a targeted nanocarrier was developed. The nanocarrier effectively delivered scutellarin to the tumor site and reversed the immune suppressive tumor microenvironment, resulting in improved therapeutic efficacy and increased survival in a mouse model of hepatocellular carcinoma, without causing toxicity.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Pharmacology & Pharmacy
Ting Li, Guangfei Ge, Hanzi Zhang, Ruyue Wang, Yiyao Liu, Qian Zhang, Zhaorong Yue, Wuli Ma, Wenbo Li, Jingjing Zhang, Hui Yang, Peiya Wang, Jiang Zhao, Yanhao Fang, Qinjian Xie, Meizhu Wang, Yang Li, Hongmei Zhu, Hongyu Li
Summary: HM-3-HSA demonstrates antitumor activity against hepatocellular carcinoma and inhibits tumor angiogenesis by binding to HUVECs and suppressing downstream protein kinases. This study reveals the mechanism by which HM-3-HSA exerts its anti-angiogenic effects.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2021)
Review
Oncology
Shant Qinxiang Sin, Chakrabhavi Dhananjaya Mohan, Robby Miguel Wen-Jing Goh, Mingliang You, Siddaiah Chandra Nayak, Lu Chen, Gautam Sethi, Kanchugarakoppal Subbegowda Rangappa, Lingzhi Wang
Summary: This review discusses the role of hypoxia and hypoxia-inducible factors (HIFs) in hepatocellular carcinoma (HCC) and their relationship with cancer hallmarks and resistance to current therapeutics. The review provides insights into potential novel therapeutic agents for managing HCC that target HIFs/hypoxic signaling pathways. It emphasizes the importance of exploring new therapeutic approaches to improve outcomes for HCC patients.
CANCER AND METASTASIS REVIEWS
(2023)
Article
Oncology
Rui Shi, Zirong Liu
Summary: RPL15 plays crucial roles in the progression and metastasis of hepatocellular carcinoma (HCC), serving as a promising candidate for targeted therapies.
CANCER CELL INTERNATIONAL
(2022)
Review
Medicine, Research & Experimental
Chuanrui Xu, Zhong Xu, Yi Zhang, Matthias Evert, Diego F. Calvisi, Xin Chen
Summary: Deregulated Wnt/β-catenin signaling is a major genetic alteration in hepatocellular carcinoma (HCC), and its activation plays an oncogenic role in hepatocarcinogenesis. The activated pathway is associated with specific gene expression patterns and pathological features, and it synergizes with other signaling cascades to promote HCC formation. Therefore, understanding and targeting this pathway has important implications for the diagnosis, classification, and personalized treatment of HCC.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Biochemistry & Molecular Biology
Ping Zhou, Nan Jiang, Guo-Xia Zhang, Qing Sun
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
(2016)
Article
Biochemistry & Molecular Biology
Min Yang, Nan Jiang, Qi-wei Cao, Mao-qiang Ma, Qing Sun
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2016)
Article
Biotechnology & Applied Microbiology
Shuqian He, Guihui Zhang, He Dong, Maoqiang Ma, Qing Sun
ONCOTARGETS AND THERAPY
(2016)
Article
Oncology
Yunfei Xu, Xiaoqing Yang, Zhen Li, Shuo Li, Sen Guo, Sayed Ismail, Hongda Liu, Zhihong Huang, Zongli Zhang, Yuxin Chen, Qing Sun
Article
Oncology
Hong-tao Liu, Lei Fang, Yu-xia Cheng, Qing Sun
Article
Oncology
Ping Zhou, He Dong, Shuqian He, Lei Fang, Nan Jiang, Qing Sun
MOLECULAR MEDICINE REPORTS
(2017)
Article
Oncology
Jing Cui, Liping Cui, Qun Liu, Qing Sun
MOLECULAR MEDICINE REPORTS
(2012)
Article
Medicine, Research & Experimental
Shufang Liu, Ying Tian, Chanchan Zhu, Xiaoqing Yang, Qing Sun
MEDICAL SCIENCE MONITOR
(2018)
Article
Pathology
Mingxia Chen, Xiaoqing Yang, Min Yang, Wei Zhang, Lei Li, Qing Sun
PATHOLOGY RESEARCH AND PRACTICE
(2019)
Article
Oncology
Juan Li, Chunyan Liu, Dawei Li, Meng Wan, Hong Zhang, Xiaoxia Zheng, Xuemei Jie, Pengju Zhang, Jingjing Li, Hongchun Hou, Qing Sun
Article
Biotechnology & Applied Microbiology
Jing Sang, Ruixue Tang, Min Yang, Qing Sun
BIOMED RESEARCH INTERNATIONAL
(2020)
Article
Oncology
Can Liu, Chao Song, Jiaxi Li, Qing Sun
CANCER MANAGEMENT AND RESEARCH
(2020)
Article
Oncology
Yuan Hao, Qing Sun
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
(2019)
Article
Oncology
Naiqing Liu, Shuxiang Sun, Xiaoqing Yang
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
(2017)